AI-powered, clinical-stage biotechnology company IGC Pharma Inc (NYSE American: IGC) announced on Wednesday that it has released additional data supporting the therapeutic potential of IGC-AD1 as a disease-modifying treatment for Alzheimer's disease. Results from preclinical studies show IGC-AD1's ability to reduce tau tangles, a key marker of Alzheimer's, and improve spatial memory in models.

The company's research indicates that IGC-AD1 decreases tau hyperphosphorylation by around 10%, while its individual component, THC, increases it by 50-75%. Additionally, IGC-AD1 reduced GSK3 enzyme expression by 35%, crucial for mitigating tau tangles, which contribute to cognitive decline.

In a separate study using an Alzheimer's mouse model, IGC-AD1 significantly improved spatial memory. Mice treated with IGC-AD1 reduced their escape latency times by 50% in Morris Water Maze tests compared to untreated models.

IGC-AD1 is currently in a Phase 2 clinical trial assessing its safety and efficacy in treating agitation in dementia due to Alzheimer's. Over 1,000 doses have been administered with no dose-limiting adverse events reported.

IGC Pharma continues to advance its portfolio, which includes treatments targeting Alzheimer's disease and other neurodegenerative conditions.